

## Insight into small molecule binding to the neonatal Fc receptor by X-ray crystallography and 100 kHz magic-angle-spinning NMR

D. Stöppler<sup>1</sup>, A. Macpherson<sup>2</sup>, S. Smith-Penzel<sup>3</sup>, N. Basse<sup>4</sup>, F. Lecomte<sup>2</sup>, H. Deboves<sup>5</sup>, R.D. Taylor<sup>2</sup>, T. Norman<sup>2</sup>, J. Porter<sup>6</sup>, L.C. Waters<sup>7</sup>, M. Westwood<sup>2</sup>, B. Cossins<sup>2</sup>, K. Cain<sup>8</sup>, J. White<sup>2</sup>, R. Griffin<sup>2</sup>, C. Prosser<sup>2</sup>, S. Kelm<sup>2</sup>, A.H. Sullivan<sup>9</sup>, D. Fox III<sup>9</sup>, M.D. Carr<sup>7</sup>, A. Henry<sup>2</sup>, R. Taylor<sup>2</sup>, B.H. Meier<sup>3</sup>, H. Oschkinat<sup>1</sup> and A. Lawson<sup>2</sup>

<sup>1</sup>Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germany, <sup>2</sup>UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE, UK, <sup>3</sup>Laboratory of Physical Chemistry, ETH Zürich, Vladimir-Prelog-Weg 2, 8093 Zürich, Switzerland, <sup>4</sup>Sanofi, 16 Rue d'Ankara, 67000 Strasbourg, France, <sup>5</sup>Evotec, 114 Innovation Dr, Milton Park, Milton, Abingdon OX14 4RZ, UK, <sup>6</sup>Midatech Pharma plc, 65 Park Dr, Innovation Dr, Milton, Abingdon OX14 4RQ, UK, <sup>7</sup>Leicester Institute of Structural and Chemical Biology, Henry Wellcome Building, University of Leicester, LE1 7HB, UK, <sup>8</sup>Vertex, Milton Park, 86-88 Jubilee Ave, Milton, Abingdon OX14 4RW, UK, <sup>9</sup>Beryllium Discovery, 3 Preston Ct, Bedford, MA 01730, USA, [oschkinat@fmp-berlin.de](mailto:oschkinat@fmp-berlin.de)

The neonatal Fc receptor (FcRn) plays a crucial role in regulation of Immunoglobulin G (IgG) and serum albumin catabolism. It is a clinically validated drug target for the treatment of autoimmune diseases caused by pathogenic antibodies, via the inhibition of its interaction with IgG. We herein present the discovery of a small molecule that binds into a conserved cavity of the heterodimeric, extra-cellular domain composed of an  $\alpha$ -chain and  $\beta$ 2-microglobulin ( $\beta$ 2m) (FcRn<sub>ECD</sub>, 373 residues). X-ray crystallography was used alongside NMR at 100 kHz Magic-Angle-Spinning (MAS) with sedimented soluble protein, to explore possibilities for refining the compound as an allosteric modulator. Proton-detected MAS NMR experiments on fully protonated [<sup>13</sup>C,<sup>15</sup>N]-labeled FcRn<sub>ECD</sub> yielded ligand-induced chemical-shift perturbations for residues in the binding pocket, and allosteric changes close to the interface of the two receptor heterodimers present in the asymmetric unit. Generating a chemical-shift-informed overlay of X-ray structures with and without ligand suggests the need of a larger ligand to displace the  $\alpha$ -chain with respect to  $\beta$ 2m, both of which participate in the FcRn<sub>ECD</sub>-IgG interaction site. Our investigation establishes a method to structurally characterize small molecule binding to non-deuterated, large proteins by NMR, even in their glycosylated form, which may prove highly valuable for structure-based drug discovery campaigns.